氟罗昔布在马匹中的长期使用。

Long-Term Firocoxib Use in Horses.

作者信息

Buzelato Carli Iuri, Fielding Langdon

机构信息

Loomis Basin Equine Medical Center, Penryn, California, USA.

出版信息

J Vet Intern Med. 2025 May-Jun;39(3):e70117. doi: 10.1111/jvim.70117.

DOI:10.1111/jvim.70117

PMID:40317502

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12046564/

Abstract

BACKGROUND

Many horses receive firocoxib over multiple years, and studies evaluating hematologic and biochemical values in these animals are lacking.

OBJECTIVE

To describe the hematologic and biochemical values of horses receiving long-term firocoxib.

ANIMALS

A total of 79 horses receiving long-term firocoxib and 153 horses not receiving long-term firocoxib and not presenting for a specific medical problem.

METHODS

Retrospective study comparing horses receiving firocoxib (F group) and no firocoxib (NF group). Signalment, hematologic, and biochemical values were compared between the two groups. Simple linear regression was used to evaluate the relationship between the duration of firocoxib administration and specific laboratory variables.

RESULTS

Horses receiving long-term firocoxib (F) were 19 (5-33) years as compared to 15 (1-33) years for the NF group (p < 0.0001). The most common reason for receiving firocoxib was osteoarthritis in 44/79 (56%) of the animals in the F group. Horses in the F group had a total protein concentration of 6.6 (5.8-8.0) g/dL as compared to 6.5 (5.1-8) g/dL in the NF group (p = 0.03). The sodium concentration for F horses was 139 (133-143) mmol/L as compared to 138 (129-145) mmol/L for NF horses (p = 0.01). Total white blood cell count was 6.11 (2.82-14.36) 10 cells/uL in the F group as compared to 6.46 (3.04-14.71) 10 cells/uL in the NF group (p = 0.03). None of the laboratory variables were associated with the duration of firocoxib administration.

CONCLUSIONS AND CLINICAL IMPORTANCE

Many horses receive firocoxib for multiple years, and equine practitioners should be aware that expected changes in laboratory values are minimal.

摘要

背景

许多马匹多年来一直使用氟罗昔康，而评估这些动物血液学和生化指标的研究尚属空白。

目的

描述长期使用氟罗昔康的马匹的血液学和生化指标。

动物

共有79匹长期使用氟罗昔康的马匹以及153匹未长期使用氟罗昔康且无特定医疗问题的马匹。

方法

对使用氟罗昔康的马匹（F组）和未使用氟罗昔康的马匹（NF组）进行回顾性研究。比较两组的特征、血液学和生化指标。采用简单线性回归评估氟罗昔康给药持续时间与特定实验室变量之间的关系。

结果

长期使用氟罗昔康的马匹（F组）年龄为19（5 - 33）岁，而NF组为15（1 - 33）岁（p < 0.0001）。F组中使用氟罗昔康的最常见原因是骨关节炎，占该组44/79（56%）的动物。F组马匹的总蛋白浓度为6.6（5.8 - 8.0）g/dL，而NF组为6.5（5.1 - 8）g/dL（p = 0.03）。F组马匹的钠浓度为139（133 - 143）mmol/L，NF组马匹为138（129 - 145）mmol/L（p = 0.01）。F组的总白细胞计数为6.11（2.82 - 14.36）×10⁹细胞/μL，NF组为6.46（3.04 - 14.71）×10⁹细胞/μL（p = 0.03）。没有实验室变量与氟罗昔康给药持续时间相关。